165 / 1068
Stockholm III Trial
Inclusion Criteria: clinically resectable RC < 15 cm from AV
R
5x5 Gy
1 Week
4 to 8 Weeks
TME
TME
5x5 Gy
25 x 2 Gy
TME
4 to 8 Weeks
Primary endpoint: Time to local recurrence, 840 pts to show equality
(15% @ 5y, power 80%)
Secondary: acute, late tox, QoL, overall survival